Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0012-186X (Print) Linking ISSN: 0012186X NLM ISO Abbreviation: Diabetologia Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin Springer Verlag
    • Subject Terms:
    • Abstract:
      Aim/hypothesis: Urotensin II is a potent vasoactive hormone and the urotensin II gene (UTS2) is localized to 1p36-p32, one of the regions reported to show possible linkage with Type 2 diabetes in Japanese subjects. The aim of this study is to investigate a possible contribution of SNPs in the UTS2 gene to the development of Type 2 diabetes.
      Methods: We surveyed SNPs in the UTS2 gene in 152 Japanese subjects with Type 2 diabetes mellitus and two control Japanese cohorts: one consisting of 122 elderly subjects who met stringent criteria for being non-diabetic, including being older than 60 years of age with no evidence of diabetes (HbA(1c)<5.6%), and another 268 subjects with normal glucose tolerance.
      Results: We identified two SNPs with amino acid substitutions, designated T21M and S89N. The allele frequency of 89N was higher in Type 2 diabetic patients than in both elderly normal subjects (p=0.0018) and subjects with normal glucose tolerance (p=0.0011), whereas the allele frequency of T21M was essentially identical in these three groups. Furthermore, in the subjects with normal glucose tolerance, 89N was associated with higher insulin concentrations on oral glucose tolerance test, suggesting reduced insulin sensitivity in subjects with 89N.
      Conclusion/interpretation: These results strongly suggest that the S89N polymorphism in the UTS2 gene is associated with the development of Type 2 diabetes, via insulin sensitivity, in Japanese subjects.
    • References:
      J Diabetes Complications. 2002 Jan-Feb;16(1):92-102. (PMID: 11872375)
      Diabetes Care. 1999 Sep;22(9):1462-70. (PMID: 10480510)
      Trends Cardiovasc Med. 2000 Aug;10(6):229-37. (PMID: 11282300)
      Br J Pharmacol. 2002 Jan;135(1):25-7. (PMID: 11786476)
      Br J Pharmacol. 2002 May;136(1):9-22. (PMID: 11976263)
      Diabetes. 2002 Apr;51(4):1247-55. (PMID: 11916952)
      Horm Metab Res. 2001 Jun;33(6):379-81. (PMID: 11456289)
      Br J Pharmacol. 2000 Aug;130(8):1865-70. (PMID: 10952676)
      Nature. 1999 Sep 16;401(6750):282-6. (PMID: 10499587)
      Biochem Biophys Res Commun. 1999 Dec 9;266(1):174-8. (PMID: 10581185)
      Br J Pharmacol. 2002 Nov;137(5):579-88. (PMID: 12381671)
      Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15803-8. (PMID: 9861051)
      Biochem Biophys Res Commun. 1999 Nov;265(1):123-9. (PMID: 10548501)
      Diabetes Care. 1992 Mar;15(3):318-68. (PMID: 1532777)
      Nat Cell Biol. 1999 Oct;1(6):383-5. (PMID: 10559967)
      Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
    • Accession Number:
      0 (Blood Glucose)
      0 (Insulin)
      0 (Urotensins)
      9047-55-6 (urotensin II)
    • Publication Date:
      Date Created: 20030628 Date Completed: 20040412 Latest Revision: 20221207
    • Publication Date:
      20240627
    • Accession Number:
      10.1007/s00125-003-1145-1
    • Accession Number:
      12830381